Variable
|
Baseline SUVmax
|
P value
|
Mid-therapy SUVmax
|
P value
|
Post-therapy SUVmax
|
P value
|
---|
n
|
Mean ± SD
|
n
|
Mean ± SD
|
n
|
Mean ± SD
|
---|
Age
| | |
0.073
| | |
0.489
| | |
0.695
|
<60 years
|
20
|
18.5 ± 8.5
| |
13
|
4.1 ± 4.9
| |
14
|
3.2 ± 3.9
| |
≥60 years
|
3
|
7.1 ± 2.6
| |
2
|
6.3 ± 7.4
| |
3
|
2.7 ± 4.6
| |
Sex
| | |
0.357
| | |
0.595
| | |
0.411
|
Male
|
17
|
17.5 ± 8.5
| |
11
|
4.0 ± 3.6
| |
13
|
3.0 ± 2.6
| |
Female
|
6
|
15.5 ± 10.3
| |
4
|
5.3 ± 8.4
| |
4
|
3.6 ± 7.3
| |
B symptoms
| | |
1.000
| | |
0.953
| | |
1.000
|
Yes
|
8
|
17.7 ± 9.1
| |
7
|
3.3 ± 3.0
| |
8
|
2.7 ± 2.5
| |
No
|
15
|
16.6 ± 9.0
| |
8
|
5.3 ± 6.3
| |
9
|
3.5 ± 5.0
| |
Bulky diseasea
| | |
0.069
| | |
0.293
| | |
0.164
|
Yes
|
4
|
24.1 ± 5.6
| |
3
|
1.8 ± 3.1
| |
2
|
4.7 ± 0.6
| |
No
|
19
|
15.5 ± 8.8
| |
12
|
5.0 ± 5.2
| |
15
|
2.9 ± 4.1
| |
ECOG scores
| | |
0.014
| | |
0.631
| | |
0.363
|
<2
|
14
|
13.4 ± 7.6
| |
9
|
5.2 ± 5.8
| |
10
|
3.0 ± 4.8
| |
≥2
|
9
|
22.6 ± 8.0
| |
6
|
3.1 ± 3.4
| |
7
|
3.3 ± 2.4
| |
Ann arbor stage
| | |
0.068
| | |
0.674
| | |
0.111
|
I–IIE
|
10
|
14.0 ± 10.5
| |
6
|
4.6 ± 4.3
| |
9
|
1.8 ± 2.8
| |
III–IVE
|
13
|
19.4 ± 6.8
| |
9
|
4.2 ± 5.6
| |
8
|
4.7 ± 4.6
| |
LDH
| | |
0.156
| | |
0.262
| | |
0.618
|
≤245
|
12
|
14.9 ± 11.3
| |
7
|
6.2 ± 6.3
| |
8
|
3.5 ± 5.3
| |
>245
|
11
|
19.3 ± 4.5
| |
8
|
2.7 ± 3.0
| |
9
|
3.0 ± 2.4
| |
IPI scores
| | |
0.114
| | |
0.368
| | |
0.176
|
≤2
|
14
|
15.0 ± 9.9
| |
9
|
5.5 ± 5.8
| |
11
|
2.8 ± 4.6
| |
>2
|
9
|
20.2 ± 6.1
| |
6
|
2.7 ± 3.1
| |
6
|
3.8 ± 2.2
| |
-
PET positron emission tomography, CT computed tomography, SUVmax the maximum standardized uptake value, ECOG eastern cooperative oncology group, LDH lactate dehydrogenase, IPI international prognostic index, SD standard deviation
-
aBulky disease, tumor diameter >10 cm